体内分布
化学
抗体
体外
癌症研究
体内
分子生物学
癌症
胰腺癌
Pet成像
共轭体系
拉顿
融合蛋白
流式细胞术
肿瘤细胞
细胞毒性
细胞培养
癌细胞
抗原
显像剂
核医学
病理
药代动力学
作者
Wenyu Wu,Guoqiang Shao,Yilin Xue,Jun Chen,Zhaoyang Zhao,Jingjing Fu,Rui Yang,Hai Qian,Chaowei Hao
标识
DOI:10.1021/acs.molpharmaceut.6c01174
摘要
Claudin 18.2 (CLDN18.2) is a tight junction protein aberrantly expressed in gastric and pancreatic cancer. In this study, we developed the novel nanobody 18.2-50H and VHH-Fc fusion antibody 18.2-50C radiolabeled with 89Zr/177Lu for CLDN18.2-targeted radiotheranostics. Zolbetuximab (IMAB362), 18.2-50H, and 18.2-50C were conjugated with DFO and labeled with 89Zr, respectively. Radiochemical purity and in vitro stability were determined by radio-TLC. CLDN18.2-targeting specificity was evaluated using HEK-293T and HEK-293T/CLDN18.2 cells. PET/CT imaging and biodistribution studies were performed in mouse models and cynomolgus monkeys. Subsequently, 177Lu-DOTA-18.2-50C was prepared and assessed for tumor targeting in gastric cancer PDX models. 89Zr-DFO-IMAB362, 89Zr-DFO-18.2-50H, and 89Zr-DFO-18.2-50C were prepared with satisfactory radiochemical yield, specific activity, and stability. Tumors were clearly visible as early as 1 h post-injection of 89Zr-DFO-18.2-50H, with an uptake value of 9.07 ± 2.36 %ID/g and a tumor-to-muscle ratio of 27.35 ± 3.72. Fc-fused 89Zr-DFO-18.2-50C exhibited improved retention and higher tumor uptake than 89Zr-DFO-18.2-50H and 89Zr-DFO-IMAB362, with % ID/g increasing continuously from 5.07 ± 0.29 at 1 h to 32.95 ± 1.57 at 168 h. Notably, the introduction of the Fc chain also markedly increased the radiation exposure in the liver and spleen. Consistently, PET imaging in cynomolgus showed that 89Zr-DFO-18.2-50C is mainly concentrated in the liver, but no apparent abnormality was observed. Furthermore, 177Lu-DOTA-18.2-50C presented remarkable tumor selectivity with prolonged retention (16.92 ± 1.94 % ID/g at 5 d post-injection) in PDX models. Nanobody 89Zr-DFO-18.2-50H demonstrated a superior tumor-to-background ratio, positioning it as a promising tracer for detecting CLDN18.2-overexpressing lesions. 89Zr/177Lu-labeled VHH-Fc antibody 18.2-50C exhibited sustained higher tumor uptake than commercially available IMAB362 and provides a novel potential candidate for CLDN18.2-targeted radionuclide therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI